EU/3/18/2068

About

On 24 August 2018, orphan designation (EU/3/18/2068) was granted by the European Commission to Novo Nordisk A/S, Denmark, for somapacitan for the treatment of growth hormone deficiency.

Somapacitan has been authorised in the EU as Sogroya since 31 March 2021. 

Key facts

Active substance
Somapacitan
Disease / condition
Treatment of growth hormone deficiency
Date of first decision
24/08/2018
Outcome
Positive
EU designation number
EU/3/18/2068

Review of designation

The Committee for Orphan Medicinal Products reviewed the orphan designation of Somapacitan at the time of marketing authorisation, and confirmed that the orphan designation should be maintained.

More information is available in the PDF icon orphan medicine assessment report .

Sponsor's contact details

Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark
Tel. +45 44 44 88 88
E-mail: webmasters@novonordisk.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

Related content

How useful was this page?

Add your rating